The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial

The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial

We examined the effects of a dihydropyridine calcium channel blocker nilvadipine with anti-inflammatory properties on cognition and cerebrospinal fluid (CSF) biomarkers by baseline Alzheimer's disease (AD) severity. Exploratory analyses were performed on the dataset (n = 497) of a phase III ran...

Full description

Bibliographic Details
Main Authors: Laila Abdullah, Fiona Crawford, Magda Tsolaki, Anne Börjesson-Hanson, Marcel Olde Rikkert, Florence Pasquier, Anders Wallin, Sean Kennelly, Ghania Ait-Ghezala, Daniel Paris, Suzanne Hendrix, Kaj Blennow, Brian Lawlor, Michael Mullan
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-03-01
Series:Frontiers in Neurology
Subjects:
mild Alzheimer's disease
nilvadipine
exploratory analysis
cognitive decline
cerebrospinal fluid Aβ42/Aβ40 ratios
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.00149/full

Internet

https://www.frontiersin.org/article/10.3389/fneur.2020.00149/full

Similar Items